Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we repo...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 15; no. 1; pp. 1 - 12
Main Authors Zhao, Wan-Hong, Wang, Bai-Yan, Chen, Li-Juan, Fu, Wei-Jun, Xu, Jie, Liu, Jie, Jin, Shi-Wei, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Zhang, Hui, Bai, Ju, Xu, Yan, Zhu, Han, Du, Juan, Jiang, Hua, Fan, Xiao-Hu, Li, Jian-Yong, Hou, Jian, Chen, Zhu, Zhang, Wang-Gang, Mi, Jian-Qing, Chen, Sai-Juan, He, Ai-Li
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 06.07.2022
BioMed Central
BMC
Subjects
Antibodies
Antigens
B cell maturation antigen
Cancer therapies
Central nervous system
Chemotherapy
Chimeric antigen receptor therapy
Chimeric antigen receptors
Cyclophosphamide
Cytokines
Diseases
Drug dosages
Drug resistance
Efficacy
Fludarabine
Hematology
Hepatitis B
Infections
Lung cancer
Lymphocytes
Lymphocytes T
Multiple myeloma
Oncology
Patients
Relapse
Safety
Stem cell transplantation
Toxicity
Virus diseases
China
Online AccessGet full text

Cover

Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. Methods LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 x 10.sup.6 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy. Results As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced [greater than or equal to] 1 adverse events (AEs). Grade [greater than or equal to] 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade [greater than or equal to] 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer. Conclusions The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285. Keywords: Multiple myeloma, Chimeric antigen receptor therapy, B cell maturation antigen, Safety, Efficacy
AbstractList LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years.BACKGROUNDLCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years.LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 × 106 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy.METHODSLEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 × 106 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy.As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade ≥ 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer.RESULTSAs of May 25, 2021, the median follow-up was 47.8 months. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade ≥ 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer.The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285.CONCLUSIONSThe 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285.
Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. Methods LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 x 10.sup.6 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy. Results As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced [greater than or equal to] 1 adverse events (AEs). Grade [greater than or equal to] 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade [greater than or equal to] 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer. Conclusions The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285. Keywords: Multiple myeloma, Chimeric antigen receptor therapy, B cell maturation antigen, Safety, Efficacy
Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. Methods LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 × 106 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy. Results As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade ≥ 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer. Conclusions The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285.
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. Methods LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 × 106 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy. Results As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade ≥ 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer. Conclusions The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM. Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285.
LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. Lymphodepletion was performed using cyclophosphamide or cyclophosphamide plus fludarabine. LCAR-B38M, at a median dose of 0.513 x 10.sup.6 cells/kg, was intravenously administered either in three split infusions or in a single infusion. The primary objective was the safety of LCAR-B38M, and the secondary objective was efficacy. As of May 25, 2021, the median follow-up was 47.8 months. All patients experienced [greater than or equal to] 1 adverse events (AEs). Grade [greater than or equal to] 3 AEs were observed in 45/74 (60.8%) patients. Cytokine release syndrome (CRS) occurred in 68/74 (91.9%) cases; 7 (9.5%) had grade [greater than or equal to] 3 CRS. One patient experienced grade 1 central nervous system toxicity. The overall response rate was 87.8%. Fifty-four out of 74 (73.0%) patients achieved complete response. The median progression-free survival was 18.0 months, and the median overall survival for all patients was not reached. The median duration of response was 23.3 months. Four patients experienced viral infection more than 6 months post-infusion, and four patients developed second primary non-hematological malignancies at a median time of 11.5 months post-CAR-T cell transfer. The 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM.
ArticleNumber 86
Audience Academic
Author Zhang, Hui
Gu, Liu-Fang
Zhang, Wang-Gang
Liu, Jie
Xu, Yan
Wang, Jian-Li
He, Ai-Li
Zhao, Wan-Hong
Mi, Jian-Qing
Chen, Sai-Juan
Zhang, Peng-Yu
Wang, Fang-Xia
Lei, Bo
Wang, Bai-Yan
Jin, Shi-Wei
Zhang, Yi-Lin
Li, Jian-Yong
Chen, Zhu
Chen, Li-Juan
Cao, Xing-Mei
Zhu, Han
Jiang, Hua
Xu, Jie
Yang, Yun
Bai, Ju
Hou, Jian
Fu, Wei-Jun
Du, Juan
Fan, Xiao-Hu
Chen, Yin-Xia
Author_xml – sequence: 1
  givenname: Wan-Hong
  surname: Zhao
  fullname: Zhao, Wan-Hong
– sequence: 2
  givenname: Bai-Yan
  surname: Wang
  fullname: Wang, Bai-Yan
– sequence: 3
  givenname: Li-Juan
  surname: Chen
  fullname: Chen, Li-Juan
– sequence: 4
  givenname: Wei-Jun
  surname: Fu
  fullname: Fu, Wei-Jun
– sequence: 5
  givenname: Jie
  surname: Xu
  fullname: Xu, Jie
– sequence: 6
  givenname: Jie
  surname: Liu
  fullname: Liu, Jie
– sequence: 7
  givenname: Shi-Wei
  surname: Jin
  fullname: Jin, Shi-Wei
– sequence: 8
  givenname: Yin-Xia
  surname: Chen
  fullname: Chen, Yin-Xia
– sequence: 9
  givenname: Xing-Mei
  surname: Cao
  fullname: Cao, Xing-Mei
– sequence: 10
  givenname: Yun
  surname: Yang
  fullname: Yang, Yun
– sequence: 11
  givenname: Yi-Lin
  surname: Zhang
  fullname: Zhang, Yi-Lin
– sequence: 12
  givenname: Fang-Xia
  surname: Wang
  fullname: Wang, Fang-Xia
– sequence: 13
  givenname: Peng-Yu
  surname: Zhang
  fullname: Zhang, Peng-Yu
– sequence: 14
  givenname: Bo
  surname: Lei
  fullname: Lei, Bo
– sequence: 15
  givenname: Liu-Fang
  surname: Gu
  fullname: Gu, Liu-Fang
– sequence: 16
  givenname: Jian-Li
  surname: Wang
  fullname: Wang, Jian-Li
– sequence: 17
  givenname: Hui
  surname: Zhang
  fullname: Zhang, Hui
– sequence: 18
  givenname: Ju
  surname: Bai
  fullname: Bai, Ju
– sequence: 19
  givenname: Yan
  surname: Xu
  fullname: Xu, Yan
– sequence: 20
  givenname: Han
  surname: Zhu
  fullname: Zhu, Han
– sequence: 21
  givenname: Juan
  surname: Du
  fullname: Du, Juan
– sequence: 22
  givenname: Hua
  surname: Jiang
  fullname: Jiang, Hua
– sequence: 23
  givenname: Xiao-Hu
  surname: Fan
  fullname: Fan, Xiao-Hu
– sequence: 24
  givenname: Jian-Yong
  surname: Li
  fullname: Li, Jian-Yong
– sequence: 25
  givenname: Jian
  surname: Hou
  fullname: Hou, Jian
– sequence: 26
  givenname: Zhu
  surname: Chen
  fullname: Chen, Zhu
– sequence: 27
  givenname: Wang-Gang
  surname: Zhang
  fullname: Zhang, Wang-Gang
– sequence: 28
  givenname: Jian-Qing
  surname: Mi
  fullname: Mi, Jian-Qing
– sequence: 29
  givenname: Sai-Juan
  surname: Chen
  fullname: Chen, Sai-Juan
– sequence: 30
  givenname: Ai-Li
  surname: He
  fullname: He, Ai-Li
BookMark eNp9kt-K1DAUxousuH_0BbwKCLLCZE2aNk29EMZxdl0YFUSvQ9okMxnSpCatMi_itc_ik5nuLLqziPSih9Pv-52c9DvNjpx3KsueYnSBMaMvIyaoKCHKc4hSiSF7kJ3gqqSQVXl-dKc-zk5j3CJEcZ2jR9kxKau6oJieZD8u_RjgTokAtLfWf4djD7wGq8X8E3xD2HtgHAjKij4qCXxItQ6iHXzYgW60g-mtAt1OWd-JV0CAfiOi-vUTz0A0bm0VFKGbAd8rB61olJ3tXa1ygwogDqPcTRMWG-MEOF8tr5Yf3sL8xePsoRY2qie377Psy-Xy8-IdXH28ul7MV7ClpBpg3RBVFaoqiwJXqMW6TJ1KkarBSEhUUUJayZAmTLe5Jlq2eamZkGWBpcSakLPses-VXmx5H0wnwo57YfhNw4c1FyEd1ypOGWpkoRXWdV1IKhtK6zKBMCK00KRIrNd7Vj82nZLTikHYA-jhF2c2fO2_8TqniUIT4PwWEPzXUcWBdya2ylrhlB8jzymjqKR1zpL02T3pNv1Hl64qqWpcYMpY-Ve1FmkB47RPc9sJyudVmogYQyipLv6hSo9UnWlT5LRJ_QPD8zuGjRJ22ERvx8F4Fw-F-V7YBh9jSs6fy8CITxHm-wjzFGF-E2E-rcbumVoziImdjmXs_6y_AUQ98tc
CitedBy_id crossref_primary_10_1080_14712598_2024_2352591
crossref_primary_10_1016_j_xkme_2024_100856
crossref_primary_10_1016_j_intimp_2022_109592
crossref_primary_10_2147_OTT_S370880
crossref_primary_10_3389_fimmu_2025_1490491
crossref_primary_10_1016_j_jgo_2023_101628
crossref_primary_10_1126_sciadv_adj6251
crossref_primary_10_3390_ijms242115674
crossref_primary_10_1186_s13045_024_01530_z
crossref_primary_10_1038_s41409_025_02525_1
crossref_primary_10_1038_s41417_024_00750_2
crossref_primary_10_3390_ijms24065994
crossref_primary_10_1111_bjh_19340
crossref_primary_10_3390_molecules29204863
crossref_primary_10_1016_j_ymthe_2024_11_013
crossref_primary_10_1016_j_jtct_2024_11_012
crossref_primary_10_1002_cpt_3057
crossref_primary_10_1038_s41591_024_02826_w
crossref_primary_10_1016_j_xcrm_2023_101214
crossref_primary_10_1016_j_jaci_2024_12_1066
crossref_primary_10_1038_s41419_023_06036_z
crossref_primary_10_1016_j_intimp_2024_112312
crossref_primary_10_1016_j_jtct_2023_10_001
crossref_primary_10_1038_s41591_024_03478_6
crossref_primary_10_3390_vaccines11111721
crossref_primary_10_1186_s12885_023_11371_7
crossref_primary_10_1016_j_ijpharm_2023_123241
crossref_primary_10_1080_13543784_2023_2249814
crossref_primary_10_2147_CMAR_S510408
crossref_primary_10_1186_s12943_022_01663_0
crossref_primary_10_3389_fimmu_2022_1005800
crossref_primary_10_1038_s41388_023_02675_w
crossref_primary_10_1038_s41423_024_01153_x
crossref_primary_10_1186_s13045_023_01479_5
crossref_primary_10_1158_2326_6066_CIR_24_0051
crossref_primary_10_1007_s00277_023_05444_7
crossref_primary_10_3389_fimmu_2024_1384002
crossref_primary_10_3389_fonc_2022_1070353
crossref_primary_10_3390_biom12091303
crossref_primary_10_1080_17460441_2024_2319672
crossref_primary_10_3389_fphar_2023_1149138
crossref_primary_10_1186_s40364_023_00543_z
crossref_primary_10_1080_10428194_2023_2284088
crossref_primary_10_1007_s11307_025_01985_7
crossref_primary_10_1080_19420862_2024_2310890
crossref_primary_10_1007_s11010_023_04906_w
crossref_primary_10_1002_hem3_70054
crossref_primary_10_1136_jitc_2023_008429
crossref_primary_10_3389_fonc_2024_1398902
crossref_primary_10_1016_j_bcp_2024_116048
crossref_primary_10_1186_s13045_023_01405_9
crossref_primary_10_3389_fimmu_2024_1433774
crossref_primary_10_1097_CM9_0000000000002476
crossref_primary_10_1186_s12967_024_05206_7
crossref_primary_10_1002_cam4_7375
crossref_primary_10_1007_s00262_024_03913_0
crossref_primary_10_1186_s12885_024_12077_0
crossref_primary_10_3389_fimmu_2022_1050522
crossref_primary_10_1016_j_transci_2023_103828
crossref_primary_10_1186_s12885_024_12263_0
crossref_primary_10_1016_j_phrs_2024_107158
crossref_primary_10_1186_s12951_024_02900_y
crossref_primary_10_3390_ijms25094996
crossref_primary_10_3389_fimmu_2023_1101495
crossref_primary_10_1007_s00432_024_05993_y
crossref_primary_10_1038_s41408_024_01068_w
crossref_primary_10_1158_2643_3230_BCD_22_0074
crossref_primary_10_1038_s41409_023_01960_2
crossref_primary_10_3389_fimmu_2023_1278749
crossref_primary_10_1182_blood_2024024523
crossref_primary_10_2217_fon_2022_1317
crossref_primary_10_1016_j_lpm_2024_104265
crossref_primary_10_1159_000543806
crossref_primary_10_1016_j_biopha_2025_117987
crossref_primary_10_1080_17474086_2024_2357274
crossref_primary_10_1177_20406207241275797
crossref_primary_10_1016_S1470_2045_23_00159_6
crossref_primary_10_1038_s41467_023_44648_3
crossref_primary_10_1186_s40164_024_00577_5
crossref_primary_10_1007_s40487_023_00230_x
crossref_primary_10_1158_1078_0432_CCR_24_0414
crossref_primary_10_1016_j_ymthe_2025_03_001
crossref_primary_10_1002_mco2_714
crossref_primary_10_1038_s41392_023_01686_z
crossref_primary_10_1186_s40364_024_00634_5
crossref_primary_10_1038_s41571_023_00754_1
crossref_primary_10_33262_ap_v5i2_1_365
crossref_primary_10_1186_s12943_024_01987_z
crossref_primary_10_1111_imm_13861
Cites_doi 10.1200/JCO.2016.71.1663
10.1182/blood-2015-07-635383
10.1056/NEJMoa1708566
10.1056/NEJMoa2024850
10.1182/blood-2014-05-552729
10.1038/leu.2013.313
10.1186/s13045-018-0681-6
10.3389/fimmu.2021.755866
10.1056/NEJMoa1709866
10.1016/j.blre.2020.100757
10.1200/JCO.2018.77.8084
10.1182/blood-2020-140243
10.1056/NEJMoa1903455
10.1016/S1470-2045(19)30788-0
10.1200/JCO.2021.39.15_suppl.8005
10.1056/NEJMoa1215134
10.2217/imt.15.77
10.1016/S0140-6736(21)00933-8
10.1038/bcj.2014.55
10.1053/j.seminhematol.2012.05.005
10.1182/blood-2021-146060
10.3389/fmed.2021.649824
10.1111/bjh.13383
10.1172/JCI126397
10.1073/pnas.1819745116
10.1182/blood-2010-10-299487
10.1182/blood-2019-124953
10.1007/s11899-017-0397-7
10.1002/ajh.23731
10.1084/jem.20031330
10.1056/NEJMoa1817226
10.1016/S1470-2045(20)30756-7
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13045-022-01301-8
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 12
ExternalDocumentID oai_doaj_org_article_680bd4fe1f994d6db669554110364f34
PMC9261106
A710608800
10_1186_s13045_022_01301_8
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 81970189
– fundername: ;
  grantid: 2018SF-002; 2017ZDXM-SF-25-6 (Approval No. 2018ZDXM-SF-039)
GroupedDBID ---
0R~
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c637t-9b3e74e7544170c1f59b37e37b10ad07633cd80f38fc2f3fdc25f8ad541dd1f33
IEDL.DBID M48
ISSN 1756-8722
IngestDate Wed Aug 27 01:20:23 EDT 2025
Thu Aug 21 18:33:02 EDT 2025
Fri Jul 11 15:31:45 EDT 2025
Fri Jul 25 09:47:29 EDT 2025
Tue Jun 17 21:28:00 EDT 2025
Tue Jun 10 20:49:33 EDT 2025
Thu May 22 21:21:33 EDT 2025
Tue Jul 01 04:23:17 EDT 2025
Thu Apr 24 23:07:05 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c637t-9b3e74e7544170c1f59b37e37b10ad07633cd80f38fc2f3fdc25f8ad541dd1f33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13045-022-01301-8
PMID 35794616
PQID 2691416885
PQPubID 54946
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_680bd4fe1f994d6db669554110364f34
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9261106
proquest_miscellaneous_2686056928
proquest_journals_2691416885
gale_infotracmisc_A710608800
gale_infotracacademiconefile_A710608800
gale_healthsolutions_A710608800
crossref_primary_10_1186_s13045_022_01301_8
crossref_citationtrail_10_1186_s13045_022_01301_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-06
PublicationDateYYYYMMDD 2022-07-06
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-06
  day: 06
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of hematology and oncology
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References N Raje (1301_CR30) 2019; 380
B-Y Wang (1301_CR11) 2019; 134
T Martin (1301_CR15) 2021; 138
SA Grupp (1301_CR5) 2013; 368
Y Que (1301_CR23) 2021; 12
M Weinstock (1301_CR22) 2015; 169
NC Munshi (1301_CR26) 2021; 384
K Kim (1301_CR24) 2014; 89
J Lu (1301_CR25) 2014; 4
SV Rajkumar (1301_CR18) 2011; 117
M D'Agostino (1301_CR4) 2017; 12
J Xu (1301_CR13) 2019; 116
CHY van Beurden-Tan (1301_CR3) 2017; 35
SJ Schuster (1301_CR7) 2017; 377
SL Maude (1301_CR6) 2018; 378
C Touzeau (1301_CR21) 2016; 127
YT Tai (1301_CR10) 2015; 7
BP O'Connor (1301_CR9) 2004; 199
JG Berdeja (1301_CR14) 2021; 398
SK Kumar (1301_CR1) 2014; 28
AD Cohen (1301_CR8) 2019; 129
WH Zhao (1301_CR12) 2018; 11
JN Brudno (1301_CR29) 2018; 36
1301_CR16
Y Qian (1301_CR32) 2021; 8
A Chari (1301_CR28) 2019; 381
DS Siegel (1301_CR2) 2012; 49
DW Lee (1301_CR17) 2014; 124
P Moreau (1301_CR20) 2021; 22
B Wang (1301_CR19) 2020; 136
C Poh (1301_CR31) 2021; 46
S Lonial (1301_CR27) 2020; 21
References_xml – volume: 35
  start-page: 1312
  year: 2017
  ident: 1301_CR3
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.71.1663
– volume: 127
  start-page: 971
  year: 2016
  ident: 1301_CR21
  publication-title: Blood
  doi: 10.1182/blood-2015-07-635383
– volume: 377
  start-page: 2545
  year: 2017
  ident: 1301_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1708566
– volume: 384
  start-page: 705
  year: 2021
  ident: 1301_CR26
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2024850
– volume: 124
  start-page: 188
  year: 2014
  ident: 1301_CR17
  publication-title: Blood
  doi: 10.1182/blood-2014-05-552729
– volume: 28
  start-page: 1122
  year: 2014
  ident: 1301_CR1
  publication-title: Leukemia
  doi: 10.1038/leu.2013.313
– volume: 11
  start-page: 141
  year: 2018
  ident: 1301_CR12
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0681-6
– volume: 12
  start-page: 755866
  year: 2021
  ident: 1301_CR23
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.755866
– volume: 378
  start-page: 439
  year: 2018
  ident: 1301_CR6
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1709866
– volume: 46
  start-page: 100757
  year: 2021
  ident: 1301_CR31
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2020.100757
– volume: 36
  start-page: 2267
  year: 2018
  ident: 1301_CR29
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.77.8084
– volume: 136
  start-page: 6
  year: 2020
  ident: 1301_CR19
  publication-title: Blood
  doi: 10.1182/blood-2020-140243
– volume: 381
  start-page: 727
  year: 2019
  ident: 1301_CR28
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1903455
– volume: 21
  start-page: 207
  year: 2020
  ident: 1301_CR27
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30788-0
– ident: 1301_CR16
  doi: 10.1200/JCO.2021.39.15_suppl.8005
– volume: 368
  start-page: 1509
  year: 2013
  ident: 1301_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1215134
– volume: 7
  start-page: 1187
  year: 2015
  ident: 1301_CR10
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.77
– volume: 398
  start-page: 314
  year: 2021
  ident: 1301_CR14
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00933-8
– volume: 4
  start-page: e239
  year: 2014
  ident: 1301_CR25
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2014.55
– volume: 49
  start-page: S3
  issue: Suppl 1
  year: 2012
  ident: 1301_CR2
  publication-title: Semin Hematol
  doi: 10.1053/j.seminhematol.2012.05.005
– volume: 138
  start-page: 549
  year: 2021
  ident: 1301_CR15
  publication-title: Blood
  doi: 10.1182/blood-2021-146060
– volume: 8
  start-page: 649824
  year: 2021
  ident: 1301_CR32
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2021.649824
– volume: 169
  start-page: 851
  year: 2015
  ident: 1301_CR22
  publication-title: Br J Haematol
  doi: 10.1111/bjh.13383
– volume: 129
  start-page: 2210
  year: 2019
  ident: 1301_CR8
  publication-title: J Clin Invest
  doi: 10.1172/JCI126397
– volume: 116
  start-page: 9543
  year: 2019
  ident: 1301_CR13
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1819745116
– volume: 117
  start-page: 4691
  year: 2011
  ident: 1301_CR18
  publication-title: Blood
  doi: 10.1182/blood-2010-10-299487
– volume: 134
  start-page: 579
  year: 2019
  ident: 1301_CR11
  publication-title: Blood
  doi: 10.1182/blood-2019-124953
– volume: 12
  start-page: 344
  year: 2017
  ident: 1301_CR4
  publication-title: Curr Hematol Malig Rep
  doi: 10.1007/s11899-017-0397-7
– volume: 89
  start-page: 751
  year: 2014
  ident: 1301_CR24
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23731
– volume: 199
  start-page: 91
  year: 2004
  ident: 1301_CR9
  publication-title: J Exp Med
  doi: 10.1084/jem.20031330
– volume: 380
  start-page: 1726
  year: 2019
  ident: 1301_CR30
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1817226
– volume: 22
  start-page: e105
  year: 2021
  ident: 1301_CR20
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30756-7
SSID ssj0061920
Score 2.5775926
Snippet Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a...
LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable...
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Antibodies
Antigens
B cell maturation antigen
Cancer therapies
Central nervous system
Chemotherapy
Chimeric antigen receptor therapy
Chimeric antigen receptors
Cyclophosphamide
Cytokines
Diseases
Drug dosages
Drug resistance
Efficacy
Fludarabine
Hematology
Hepatitis B
Infections
Lung cancer
Lymphocytes
Lymphocytes T
Multiple myeloma
Oncology
Patients
Relapse
Safety
Stem cell transplantation
Toxicity
Virus diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxFMUFjASEiBqbRwnjsOtu7Ss0HYPiJX2Zjl-aFdqk6oPof4RzvwWfhkzTlptQIILtyoeq7FnPI945htCXsuiCLkxJbMuTxh44IoZg9VoCH1SmUrkJdYOT8_l6UX2-TK_vNHqC3PCWnjgduOOpEoqlwXPQ1lm2P1IyhJMIFgtIbMgIhIo2LxdMNXqYIwKkl2JjJJHK44Xggwz1_GmjjPVM0MRrf9Pnfx7nuQNwzO5R-52HiMdtW96n9zy9QNye9rdiT8k3ydAwbYgsTQAU5tvbLOgTaBnJ6Mv7FioKb2uKZasLFbe0WYJv8MydtnZ0l06IZ1v_ayZmw_U0MUVGLafP_iQ4meEmWdmOR9S7LLFQGL8bNjOwrf1SxrhafEfYiNu-vZs_Gl8_pGl7x6Ri8n468kp67otMCtFsWZlJXyR-SI2JUssDzk8KbwoKp4Yl4AeEtapJAgVbBpEcDbNgzIOeOEcD0I8Jgd1U_snhKbOupQbZUwF8VoJPpH3wlglwEw6xc2A8N3ma9tBkWNHjJmOIYmSumWYBobpyDCtBuT9fs6iBeL4K_Ux8nRPiSDa8QGIlu5ES_9LtAbkJUqEbitS96pAj8Ark6Cdk2RA3kQKVAawAGu6mgbYBoTV6lEe9ijhENv-8E7qdKdEVjqVJQd_Wal8QF7th3EmJsbVvtkgjYKAVJYpLLnoSWtv7f2R-voqAomXED7DGzz9H5v1jNxJ4_nCbMpDcrBebvxz8NfW1Yt4NH8BBoM5tQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXxKcoDDASEiBqLY4Tx-EFdaNlQuseEJP6Zjn-YJPapPRDqH8I_y93bloISHuL4rMS-87nO_vud4S8lkURcmNKZl2eMLDAFTMGs9EQ-qQylchLzB0en8vTi-zLJJ-0B27LNqxypxOjonaNxTPyo1SWHIwHpfKP8x8Mq0bh7WpbQuMmuYXQZSjVxWTvcKFvkOwSZZQ8WnK8FmQYv473dZypzmYUMfv_18z_Rkv-tf2M7pG7rd1IB1tG3yc3fP2A3B63N-MPya8RULANyC0NwNrmJ1vPaRPo2cngKzsWakyvaoqJK_Old7RZwHNYxFo7G7oLKqSzjZ82M_OBGjq_hO2N8j7Fs4SpZ2Yx61MstcVAbPy0v-2EP-sXNGLU4gdiNW769mz4eXj-iaXvHpGL0fDbySlrSy4wK0WxYmUlfJH5IlYmSywPObwpvCgqnhiXgDIS1qkkCBVsGkRwNs2DMi7PuHM8CPGYHNRN7Z8QmjrrUm6UMRU4bSUYRt4LY5WAvdIpbnqE7-Ze2xaPHMtiTHX0S5TUW35p4JeO_NKqR97v-8y3aBzXUh8jS_eUiKQdXzSL77pdmFqqpHJZ8DyUZYbVtaQswcQCq0jILIisR16iQOhtWupeH-gBmGYSVHSS9MibSIEaAQZgTZvYANOA2FodysMOJaxk223eCZ1uNclS_5H7Hnm1b8aeGB1X-2aNNAq8UlmmMOSiI6ydsXdb6qvLiCZegg8Nf_D0-o8_I3fSuHAwWPKQHKwWa_8czLFV9SKuud-dgzD0
  priority: 102
  providerName: ProQuest
Title Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
URI https://www.proquest.com/docview/2691416885
https://www.proquest.com/docview/2686056928
https://pubmed.ncbi.nlm.nih.gov/PMC9261106
https://doaj.org/article/680bd4fe1f994d6db669554110364f34
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ti9MwONwLiF_EV5yeM4LgBxdtmjZNBZHtuHEMd8jpYN9K2ibewdbObkP3F_zVPk_aDqvHfdponmxJnvfmeSHktYwiG2odsywPPQYWuGJaYzYalj5JdSrCGHOHpxfyfBZM5uH8gLTtjpoDXN_o2mE_qVm1ePfrx-4TMPxHx_BKvl9zvO5jGJeO93CcqUNyDJopwo4G02B_q4C-Qp0gGUqQAr7fJtHc-BsdReXq-f8vtf-NpPxLNY3vk3uNTUmHNRE8IAemeEjuTJtb80fk9xgg2A5omlpAe_mTbVe0tPTz6fCSjYSa0uuCYlLLam1yWlbw3VauD8-OtgGHdLkzi3KpP1BNV1eg-igfUHzPsDBMV8sBxWNjQFJmMagn4WJNRV39WvwD16n7MZmNz76dnrOmBwPLpIg2LE6FiQITuVZlXsZtCE8iI6KUezr3QDqJLFeeFcpmvhU2z_zQKp2HAc9zboV4Qo6KsjBPCfXzLPe5Vlqn4MXFYCkZI3SmBCjPXHHdI7w98CRrCpRjn4xF4hwVJZMaSQkgKXFISlSPvN3PWdXlOW6FHiEe95BYWts9KKvvScOpiVRemgfWcBvHAbbbkjIGmwvMJCEDK4IeeYlUkNR5qnsBkQzBVpMgsz2vR944CCRa2ECmm0wHOAYsttWBPOlAAmtn3eGW0pKWMxJfxhysaKXCHnm1H8aZGC5XmHKLMArcVBn7sOWoQ6GdvXdHiusrV148BqcaVvDs9rU9J3d9xy0YPXlCjjbV1rwA-2yT9slhNI_65Hg4nHydwOfo7OLLZd-97eg7hvwD3Fo4BQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1JqGBLwgrqIwmJFAgJi1JM7FQUKo21o61vYBbVLfPCe22aS2Kb1o6ofwG3wj5zhJISDtbW-RfSzHPsfnYp8LIa_jJLGRUinLdeQx0MAFUwqj0TD1SaYyHqUYOzwYxr2z8OsoGm2RX3UsDLpV1jzRMWpd5HhHvh_EqQ_KgxDR59kPhlWj8HW1LqFRksWJWV-Bybb4dHwE-H0TBN3O6WGPVVUFWB7zZMnSjJskNIkrvuXlvo2gJTE8yXxPaTDrOc-18CwXNg8stzoPIiuUjkJfa9_iBSiw_FsgeD009pLRxsBDW8SrA3NEvL_w8RmSob88vg_6TDSEn6sR8L8k-Nc78y9x171P7lV6Km2XhPWAbJnpQ3J7UL3EPyI_uwDB1rAh1AIpFVdsNaOFpf3D9jd2wMWAXk4pBsrMFkbTYg7fdu5q-6xp7cRIJ2szLibqI1V0dgHilPp7FO8uxoap-WSPYmkvBmRqxnvlIPxZM6cuJy5O4Kp_03f9zpfO8IgF7x-TsxtBxhOyPS2m5imhgc514CuhVAZGYgqKmDFc5YKDbNbCVy3i13sv8yr_OZbhGEtnB4lYlviSgC_p8CVFi3zYjJmV2T-uhT5AlG4gMXO3ayjm32XFCGQsvEyH1vg2TUOs5hXHKah0oIXxOLQ8bJFdJAhZhsFu-I9sgyoYg0jwvBZ56yCQA8ECclUFUsA2YC6vBuROAxI4R97srolOVpxrIf-csxZ5tenGkeiNNzXFCmEEWMFxGsCSkwaxNtbe7JleXrjs5SnY7PAHz66ffJfc6Z0O-rJ_PDx5Tu4G7hCho-YO2V7OV-YFqILL7KU7f5Sc3_SB_w1Wh235
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Four-year+follow-up+of+LCAR-B38M+in+relapsed+or+refractory+multiple+myeloma%3A+a+phase+1%2C+single-arm%2C+open-label%2C+multicenter+study+in+China&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Zhao%2C+Wan-Hong&rft.au=Wang%2C+Bai-Yan&rft.au=Chen%2C+Li-Juan&rft.au=Fu%2C+Wei-Jun&rft.date=2022-07-06&rft.pub=BioMed+Central+Ltd&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-022-01301-8&rft.externalDocID=A710608800
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon